CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 63 filers reported holding CYTOMX THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $4,497,000 | +56.9% | 418,364 | +120.4% | 0.01% | +50.0% |
| Q4 2018 | $2,866,000 | -58.1% | 189,824 | -48.6% | 0.00% | 0.0% |
| Q3 2018 | $6,836,000 | +81.6% | 369,502 | +124.3% | 0.00% | -20.0% |
| Q2 2018 | $3,765,000 | -8.0% | 164,708 | +14.5% | 0.01% | 0.0% |
| Q1 2018 | $4,092,000 | +261.5% | 143,823 | +168.2% | 0.01% | +400.0% |
| Q4 2017 | $1,132,000 | +19.3% | 53,623 | +2.7% | 0.00% | 0.0% |
| Q3 2017 | $949,000 | +17.3% | 52,211 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $809,000 | +33.9% | 52,211 | +49.3% | 0.00% | 0.0% |
| Q1 2017 | $604,000 | +57.3% | 34,961 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $384,000 | -25.3% | 34,961 | +6.7% | 0.00% | 0.0% |
| Q3 2016 | $514,000 | +53.4% | 32,752 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $335,000 | +238.4% | 32,752 | +327.4% | 0.00% | – |
| Q1 2016 | $99,000 | -38.1% | 7,663 | 0.0% | 0.00% | – |
| Q4 2015 | $160,000 | – | 7,663 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,500,000 | $7,635,000 | 1.78% |
| Altium Capital Management LP | 1,233,642 | $6,279,000 | 1.65% |
| RA Capital Management | 3,500,000 | $17,815,000 | 0.25% |
| Soleus Capital Management, L.P. | 261,050 | $1,329,000 | 0.21% |
| Affinity Asset Advisors, LLC | 125,000 | $636,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,078,103 | $5,488,000 | 0.16% |
| Point72 Asset Management, L.P. | 6,303,025 | $32,082,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 249,146 | $1,268,000 | 0.13% |
| Candriam S.C.A. | 3,305,940 | $16,826,000 | 0.11% |
| RTW INVESTMENTS, LP | 1,400,939 | $7,131,000 | 0.11% |